Study of Y90-Radioembolization With Nivolumab in Asians With Hepatocellular Carcinoma

Launched by NATIONAL CANCER CENTRE, SINGAPORE · Jan 24, 2017

Keywords

ClinConnect Summary

This clinical trial is exploring how effective a treatment combining Y90 radioembolization and a medication called nivolumab is for patients with liver cancer, specifically hepatocellular carcinoma (HCC), that cannot be removed through surgery or liver transplant. The trial is currently active but not recruiting new participants. It's aimed at adults aged 21 and older who have measurable liver lesions and meet specific health criteria, such as having a certain level of liver function and not having received prior Y90 treatments.

Participants in this trial can expect to undergo a procedure called Y90 radioembolization, which delivers radiation directly to the liver tumors, along with receiving nivolumab, which helps boost the body's immune response against cancer. It's important for potential participants to know that they should not have other serious health issues or treatments that could interfere with the study, and women of childbearing age will need to take precautions to avoid pregnancy during the trial. Overall, this study aims to find new ways to help manage liver cancer in patients who have limited treatment options.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients with hepatocellular carcinoma (HCC) that is not suitable for resection or liver transplant, who are planned for Y90 radioembolization as per institutional practice.
• • 2. Patients must have measurable disease with target lesion in liver, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as \>20 mm with conventional techniques or as \>10 mm with spiral CT scan.
• • 3. Diagnosis of HCC confirmed by histology/cytology or clinically by AASLD criteria in cirrhotic subjects. Patients without cirrhosis require histological confirmation of diagnosis
• • 4. No prior Y90 radioembolization therapy. Prior local therapies, such as surgery, hepatic artery embolization/chemoembolization, radiofrequency ablation, percutaneous ethanol injection or cryoabalastion is allowed, if the index lesion(s) remains outside of the treatment field or has progressed since prior treatment. Local therapy must have been completed at least 4 weeks prior to the baseline scan
• • 5. Age ≥ 21 years.
• • 6. ECOG performance status ≤ 2
• • 7. Life expectancy of greater than 3 months
• • 8. Only patients with Child-Pugh score for liver cirrhosis of A (sum of scores for five parameters: 5-6) will be allowed into this trial
• • 9. Subjects with HBV infection must be on antiviral therapy per regional standard of care guidelines prior to initiation of study therapy. Both HBeAg positive and negative subjects will be included.
• • 10. Patients must have lesions in the liver that are amenable to CT-guided liver biopsy
• 11. Patients must have normal organ and marrow function as defined below:
• • Haemoglobin ≥ 8.5g/dL
• • Absolute Neutrophil Count ≥ 1.5 x 10\^9/L
• • Platelets ≥ 50 x 10\^9/L
• • Total Bilirubin \< 3 mg/dL
• • AST(SGOT)/ALT (SGPT) ≤ 3 x ULN
• • Creatinine ≤ 1.5 x ULN or measured/calculated Creatinine Clearance (CrCl) ≥ 60 ml/min
• • 12. Ability to understand and the willingness to sign a written informed consent document.
• • 13. Any surgery must be more than 28 days before start of study drug and any surgical wounds must be completely healed
• • 14. Female subjects of childbearing potential must have a negative serum or urine pregnancy test within 3 days prior to receiving the first dose of study medication, and must agree to adequate contraception use from time of signing the informed consent through to 120 days after the last dose of the study drug. Male subjects must agree to adequate contraception use from time of signing the informed consent through 120 days after the last dose of the study drug.
• Exclusion Criteria:
• • 1. Patients are excluded if they are receiving any other investigational agents or using an investigational device within 4 weeks of first dose of treatment. Patients are excluded if they are receiving other systemic therapy within 2 weeks of first dose of treatment.
• • 2. Patients with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events.
• • 3. Prior use of anti-PD1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4 antibody, or any drug specifically targeted T-cell costimulatory checkpoint pathways
• • 4. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, uncontrolled hypertension or psychiatric illness/social situations that would limit compliance with study requirements.
• • 5. Subjects with any active autoimmune disease or history of known or suspected autoimmune disease requiring systemic therapy within the past 2 years, except for subjects with vitiligo, resolved childhood asthma/atopy or euthyroid patients with a history of Grave's disease (subjects with suspected autoimmune thyroid disorders must be negative for thyroglobulin and thyroid peroxidase antibodies and thyroid stimulating immunoglobulin prior to randomization). Replacement therapy (e.g. with thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency etc) is not considered a form of systemic treatment
• • 6. Pregnant women or breastfeeding mothers are excluded from this study because of the potential risks to the foetus or baby. Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
• • 7. Diagnosis of immunodeficiency, including HIV/AIDS
• • 8. Prior organ allograft or allogeneic bone marrow transplantation
• • 9. History of severe hypersensitivity reactions to other monoclonal antibodies.
• • 10. Prisoners or subjects who are involuntarily incarcerated
• • 11. Subjects who are compulsorily detained for treatment of either a psychiatric or physical (eg, infectious disease) illness
• • 12. Inability to comply with restrictions and prohibited activities/treatments in this study
• • 13. Chronic treatment with systemic steroids or other immunosuppressive agent.
• • 14. Subjects with concomitant second malignancies (except adequately treated non-melanomatous skin cancers, in situ cervical cancers, localized prostate cancer or in situ breast cancer) are excluded unless a complete remission was achieved at least 3 years prior to study entry and no additional therapy is required or anticipated to be required
• • 15. Prior radiation therapy to the liver or upper abdomen
• • 16. Inability to undergo Y-90 radioembolisation due to inability to cathterise the hepatic artery, portal vein thrombosis/occlusion limiting the ability to perform selective infusion, Tc-99M MAA scan showing unfavourable shunt fraction between the liver and pulmonary parenchyma, any other contraindications to RE as determined by the interventional radiologist (e.g. other anatomic variants precluding safe administration of Y90, severe peripheral vascular disease, uncorrectable coagulopathy etc)